Immatics Net Borrowings Over Time
| IMTX Stock | USD 6.85 0.03 0.44% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Immatics Performance and Immatics Correlation. Immatics |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share 0.766 | Quarterly Revenue Growth (0.16) | Return On Assets (0.12) | Return On Equity (0.24) |
The market value of Immatics NV is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics' value that differs from its market value or its book value, called intrinsic value, which is Immatics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics' market value can be influenced by many factors that don't directly affect Immatics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immatics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Borrowings Analysis
Compare Immatics NV and related stocks such as Crinetics Pharmaceuticals, Alx Oncology Holdings, and Bioatla Net Borrowings Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRNX | (48 K) | (48 K) | (48 K) | (48 K) | (48 K) | (48 K) | (48 K) | (212 K) | (212 K) | (212 K) | (212 K) | (212 K) | (212 K) | (190.8 K) | (200.3 K) |
| ALXO | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | (6.5 M) | (281 K) | 9.3 M | 10.7 M | 11.3 M |
| BCAB | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 4 M | 3.4 M | 3.4 M | 3.4 M | 3.1 M | 3.3 M |
| AVTE | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.2 M | 2 M |
| KROS | (420 K) | (420 K) | (420 K) | (420 K) | (420 K) | (420 K) | (420 K) | (420 K) | (420 K) | (420 K) | (420 K) | (420 K) | (420 K) | (378 K) | (396.9 K) |
| SNDX | 14 M | 14 M | 14 M | 14 M | 14 M | (9 M) | 19.7 M | 19.7 M | 19.7 M | 19.7 M | 19.7 M | (21 M) | (21 M) | (18.9 M) | (18 M) |
| MLYS | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.5 M | 3.1 M |
| REPL | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 10 M | (10.8 M) | (264 K) | (264 K) | (237.6 K) | (225.7 K) |
| JANX | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 2.5 M | 180.5 M | 23.4 M | 26.9 M | 25.6 M |
| FENC | 0.0 | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 20.2 M | 23.2 M | 24.4 M |
| EWTX | (251 K) | (251 K) | (251 K) | (251 K) | (251 K) | (251 K) | (251 K) | (251 K) | (251 K) | (251 K) | (251 K) | (251 K) | (251 K) | (225.9 K) | (237.2 K) |
| HRMY | 100 M | 100 M | 100 M | 100 M | 100 M | 100 M | 100 M | 100 M | 100 M | 100 M | 97.5 M | (500 K) | (2 M) | (1.8 M) | (1.7 M) |
| INBX | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | (5 M) | (5.7 M) | 33.8 M | 41.4 M | 40 M | 128.9 M | 148.2 M | 155.6 M |
| MRUS | (167 K) | (167 K) | (167 K) | (167 K) | (167 K) | 8.5 M | (167 K) | (486 K) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| KRON | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (30 K) | 151.2 M | (5 K) | (5 K) | (5.8 K) | (5.5 K) |
Immatics NV and related stocks such as Crinetics Pharmaceuticals, Alx Oncology Holdings, and Bioatla Net Borrowings description
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.My Equities
My Current Equities and Potential Positions
| Immatics NV | IMTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Germany |
| Exchange | NASDAQ Exchange |
USD 6.85
Additional Tools for Immatics Stock Analysis
When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.